Jin Medical International Ltd. declined 1.56% in after-hours trading. The company's stock price movement may be influenced by the recent news event related to Precision Medicine (PM) in Alzheimer's Disease (AD). The observed efficacy treatment effects from Blarcamesine clinical AD trial confirms the identified PM patient population, which could potentially impact the company's future prospects and investor sentiment.
Comments
No comments yet